The effect of SGLT2 inhibition on prostate cancer Mendelian randomization and observational analysis using electronic healthcare and cohort data

被引：1

作者：

Zheng, Jie ^{[1
,2
,3
]}

Lu, Jieli ^{[1
,2
]}

Qi, Jiying ^{[1
,2
]}

Yang, Qian ^{[3
]}

Zhao, Huiling ^{[3
]}

Liu, Haoyu ^{[1
,2
]}

Chen, Zhihe ^{[1
,2
]}

Huang, Lanhui ^{[1
,2
]}

Ye, Youqiong ^{[4
,5
]}

Xu, Min ^{[1
,2
]}

Xu, Yu ^{[1
,2
]}

Wang, Tiange ^{[1
,2
]}

Li, Mian ^{[1
,2
]}

Zhao, Zhiyun ^{[1
,2
]}

Zheng, Ruizhi ^{[1
,2
]}

Wang, Shuangyuan ^{[1
,2
]}

Lin, Hong ^{[1
,2
]}

Hu, Chunyan ^{[1
,2
]}

Chui, Celine Sze Ling ^{[6
,7
,8
]}

Yeung, Shiu Lun Au ^{[7
]}

Luo, Shan ^{[3
,7
]}

Dimopoulou, Olympia ^{[3
,9
]}

Dixon, Padraig ^{[3
,10
]}

Harrison, Sean ^{[3
,10
]}

Liu, Yi ^{[3
]}

Robinson, Jamie ^{[3
]}

Yarmolinsky, James ^{[3
]}

Haycock, Philip ^{[3
]}

Yuan, Jinqiu ^{[12
,13
,14
,15
]}

Lewis, Sarah ^{[3
]}

Yuan, Zhongshang ^{[16
]}

Gaunt, Tom R. ^{[3
,11
,17
,18
]}

Smith, George Davey ^{[3
,11
,17
,18
]}

Ning, Guang ^{[1
,2
]}

Martin, Richard M. ^{[3
,7
,17
,18
]}

Cui, Bin ^{[1
,2
]}

Wang, Weiqing ^{[1
,2
]}

Bi, Yufang ^{[1
,2
]}

机构：

[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine & Metab Dis, Dept Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Natl Clin Res Ctr Metab Dis, Natl Hlth Commiss PR China,Shanghai Digital Med In, Shanghai, Peoples R China

[3] Univ Bristol, Bristol Med Sch, MRC Integrat Epidemiol Unit IEU, Oakfield House, Bristol BS8 2BN, England

[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Immunol, Ctr Immune Related Dis,Sch Med, Shanghai, Peoples R China

[5] Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Dept Immunol & Microbiol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200025, Peoples R China

[6] Univ Hong Kong, Li Ka Shing Fac Med, Sch Nursing, Hong Kong, Peoples R China

[7] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China

[8] Lab Data Discovery Hlth D24H, Hong Kong Sci Pk,Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China

[9] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol BS8 2PS, England

[10] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England

[11] Univ Bristol, Bristol Med Sch, Dept Populat Hlth Sci, Bristol BS8 2BN, England

[12] Sun Yat sen Univ, Affiliated Hosp 7, Clin Res Ctr, Shenzhen 518107, Guangdong, Peoples R China

[13] Sun Yat sen Univ, Affiliated Hosp 7, Ctr Digest Dis, Shenzhen 518107, Guangdong, Peoples R China

[14] Guangzhou Women & Children Med Ctr, Guangzhou 510623, Guangdong, Peoples R China

[15] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Div Epidemiol, Hong Kong, Peoples R China

[16] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Biostat, Jinan, Peoples R China

[17] Univ Hosp Bristol & Weston NHS Fdn Trust, NIHR Biomed Res Ctr, Bristol, England

[18] Univ Bristol, Bristol, England

来源：

CELL REPORTS MEDICINE | 2024年 / 5卷 / 08期

基金：

中国国家自然科学基金; 英国医学研究理事会; 英国惠康基金;

关键词：

RISK; EPIDEMIOLOGY; ASSOCIATION; INSTRUMENTS; MEDICATION; UPDATE; ADULTS;

D O I：

10.1016/j.xcrm.2024.101688

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

We evaluated the effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on prostate cancer by evidence triangulation. Using Mendelian randomization, we found that genetically proxied SGLT2 inhibition reduced the risk of overall (odds ratio = 0.56, 95% confidence interval [CI] = 0.38 to 0.82; 79,148 prostate cancer cases and 61,106 controls), advanced, and early-onset prostate cancer. Using electronic healthcare data ( n SGLT2i = 24,155; n DPP4i = 24,155), we found that the use of SGLT2 inhibitors was associated with a 23% reduced risk of prostate cancer (hazard ratio = 0.77, 95% CI = 0.61 to 0.99) in men with diabetes. Using data from two prospective cohorts ( n 4C = 57,779; n UK_Biobank = 165,430), we found little evidence to support the association of HbA1c 1c with prostate cancer, implying a non-glycemic effect of SGLT2 inhibition on prostate cancer. In summary, this study provides multiple layers of evidence to support the beneficial effect of SGLT2 inhibition on reducing prostate cancer risk. Future trials are warranted to investigate whether SGLT2 inhibitors can be recommended for prostate cancer prevention.

引用

页数：17

共 50 条

[41] Identifying Confounders Using Bayesian Networks and Estimating Treatment Effect in Prostate Cancer With Observational Data
Sieswerda, Melle
Xie, Shixuan
van Rossum, Ruby
Bermejo, Inigo
Geleijnse, Gijs
Aben, Katja
van Erning, Felice
Lemmens, Valery
Dekker, Andre
Verbeek, Xander
JCO CLINICAL CANCER INFORMATICS, 2023, 7 : e2200080
[42] The effect of comorbidities on diagnostic interval for lung cancer in England: a cohort study using electronic health record data
Rogers, Imogen
Cooper, Max
Memon, Anjum
Forbes, Lindsay
van Marwijk, Harm
Ford, Elizabeth
BRITISH JOURNAL OF CANCER, 2024, 131 (07) : 1147 - 1157
[43] Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
Xinyu Li
Rudolf Hoogenveen
Mohamed El Alili
Saskia Knies
Junfeng Wang
Joline W. J. Beulens
Petra J. M. Elders
Giel Nijpels
Anoukh van Giessen
Talitha L. Feenstra
PharmacoEconomics, 2023, 41 : 1249 - 1262
[44] Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
Li, Xinyu
Hoogenveen, Rudolf
El Alili, Mohamed
Knies, Saskia
Wang, Junfeng
Beulens, Joline W. J.
Elders, Petra J. M.
Nijpels, Giel
van Giessen, Anoukh
Feenstra, Talitha L.
PHARMACOECONOMICS, 2023, 41 (10) : 1249 - 1262
[45] Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among patients with cancer treated with anthracycline: A systematic review and meta-analysis
Wannaphut, Chalothorn
Wattanachayakul, Phuuwadith
Saowapa, Sakditad
Ponvilawan, Ben
Tanariyakul, Manasawee
Kewcharoen, Jakrin
Yingchoncharoen, Pitchaporn
Aiumtrakul, Noppawit
Acoba, Jared David
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] What effect do sodium-glucose co-transporter-2 (SGLT2) inhibitors have on heart failure in real-world clinical practice? A meta-analysis of observational studies
Hinton, W.
Ansari, A. S.
Whyte, M. B.
McGovern, A. P.
Feher, M. D.
Munro, N.
de Lusignan, S.
DIABETIC MEDICINE, 2021, 38
[47] Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis
Wannaphut, Chalothorn
Wattanachayakul, Phuuwadith
Saowapa, Sakditad
Ponvilawan, Ben
Tanariyakul, Manasawee
Kewcharoen, Jakrin
Yingchoncharoen, Pitchaporn
Suenghataiphorn, Thanathip
Aiumtrakul, Noppawit
Acoba, Jared
ECANCERMEDICALSCIENCE, 2025, 19
[48] Epidemiology of endometriosis in Kazakhstan: a national population-based cohort analysis (2014-2019) using data from the national electronic healthcare system
Aimagambetova, Gulzhanat
Sakko, Yesbolat
Ukybassova, Talshyn
Terzic, Milan
Marat, Aizada
Kamzayeva, Nazira
Gusmanov, Arnur
Zhakhina, Gulnur
Yerdessov, Sauran
Mussina, Kamilla
Syssoyev, Dmitriy
Gaipov, Abduzhappar
FRONTIERS IN MEDICINE, 2025, 11
[49] Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data
Neuen, Brendon L.
Jun, Min
Wick, James
Kotwal, Sradha
Badve, Sunil, V
Jardine, Meg J.
Gallagher, Martin
Chalmers, John
Nallaiah, Kellie
Perkovic, Vlado
Peiris, David
Rodgers, Anthony
Woodward, Mark
Ronksley, Paul E.
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 43
[50] HOXB13 G84E Mutation and Prostate Cancer Risk: Kin-Cohort Analysis Using Data From the UK Genetic Prostate Cancer Study
Nyberg, Tommy
Dadaev, Tokhir
Govindasami, Koveela
Lee, Andrew
Leslie, Malgorzata
Kote-Jarai, Zsofia
Eeles, Rosalind
Antoniou, Antonis C.
GENETIC EPIDEMIOLOGY, 2017, 41 (07) : 676 - 676

← 1 2 3 4 5 →